Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study

References

• Ramakrishnan MS, Yu Y, VanderBeek BL. Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial. JAMA Ophthalmol. 2020;138(3):237. doi:10.1001/jamaophthalmol.2019.4577
   PubMed Web of Science ®Google Scholar
• Park WB, Choe PG, Kim S-H, et al. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. J Intern Med. 2007;261(3):268–275. doi:10.1111/j.1365-2796.2006.01762.x
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–414. doi:10.1001/archderm.140.4.408
   PubMedGoogle Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–897. doi:10.1111/j.1365-2133.2004.06174.x
   PubMed Web of Science ®Google Scholar
• Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatol Basel Switz. 2011;222(4):363–374. doi:10.1159/000329026
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. doi:10.1016/j.jaad.2008.12.032
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Heaton E, Levender MM, Feldman SR. Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions. J Dermatol Treat. 2013;24(2):82–88. doi:10.3109/09546634.2011.588194
   PubMed Web of Science ®Google Scholar
• Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006;55(4):637–641. doi:10.1016/j.jaad.2006.05.026
   PubMed Web of Science ®Google Scholar
• Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–667. doi:10.1684/ejd.2012.1802
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatol Basel Switz. 2006;213(4):319–326. doi:10.1159/000096069
   PubMed Web of Science ®Google Scholar
• Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12:667–682.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–2355. doi:10.1111/jdv.13230
   PubMed Web of Science ®Google Scholar
• Balato N, Megna M, Di Costanzo L, et al. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Br J Dermatol. 2013;168(1):201–205. doi:10.1111/j.1365-2133.2012.11205.x
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Andersen KH, et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol. 2018;179(5):1062–1071. doi:10.1111/bjd.16667
   PubMed Web of Science ®Google Scholar
• National Healthcare Security Administration. Development statistics bulletin of national basic medical insurance. 2018. Available from: http://www.nhsa.gov.cn. Accessed April 11, 2020.
   Google Scholar
• Giordano TP, Gifford AL, White AC, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–1499. doi:10.1086/516778
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Lin H, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48(2):248–256. doi:10.1086/595705
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PCM, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323. doi:10.1046/j.1365-2133.2002.04967.x
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–166. doi:10.1111/j.1365-2133.2009.09116.x
   PubMed Web of Science ®Google Scholar
• Ma L, Yang Q, Yang H, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2016;55(1):106–113. doi:10.1111/ijd.12788
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized Phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197–205. doi:10.1111/bjd.15466
   PubMed Web of Science ®Google Scholar